CDK6:对T-ALL/LBLL是一个有吸引力的治疗标
Wei Li1, Jamie Katy Hu2, Miaofen G Hu1
1Department of Medicine, Division of Hematology and Oncology, Tufts Medical Center, Boston, USA.
Expert opinion on therapeutic targets
|November 17, 2023
概括
准循环素依赖性激酶6 (CDK6) 途径对治疗T细胞急性淋巴细胞白血病 (T-ALL) 有希望. 在动物模型中抑制CDK6阻断了癌症生长,为这种侵袭性白血病提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 人类T细胞急性淋巴细胞白血病/T细胞淋巴细胞淋巴瘤 (T-ALL/LBL) 在当前化疗中长期存活率较低 (<20%).
- 对T-ALL/LBL有效和安全的治疗方法仍然难以捉摸,需要新的治疗策略.
- 确定调节T-ALL扩散和生存的关键途径对于开发新疗法至关重要.
研究的目的:
- 审查了解T-ALL中循环素依赖性激酶6 (CDK6) 途径的作用的最新进展.
- 阐明CDK6及其网络在T-ALL细胞增殖,存活和代谢中的基本功能.
- 提供对CDK6作用机制的见解,以确定新的治疗途径.
主要方法:
- 对T-ALL中CDK6的最新科学文献的审查.
- 从动物模型中分析临床前数据.
- 检查正在进行的涉及CDK4/6抑制剂的临床试验.
主要成果:
- 在动物模型中,CDK6通路的抑制阻断了T-ALL的启动,生长和生存.
- CDK6及其网络在T-ALL细胞的增殖,生存和新陈代谢中起着至关重要的作用.
- 目前正在进行CDK4/6抑制剂的临床试验,用于T-ALL治疗.
结论:
- CDK6是T-ALL.的重要治疗点.
- 抑制CDK6,单独或组合,具有延迟进展和根除T-ALL的潜力.
- 对CDK6通路的进一步研究可能会导致T-ALL/LBL的有效治疗方法.
关键词:
循环素依赖性激酶6 (CDK6) 是一种T细胞急性淋巴细胞白血病/T细胞淋巴细胞淋巴瘤 (T-ALL/LBL)细胞周期调节器细胞周期调节器代谢 代谢 代谢 代谢肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖 肥胖更多相关视频
10:33Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
Published on: October 26, 2015
11.4K
10:49Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.2K
相关概念视频
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
M-Cdk Drives Transition Into Mitosis
5.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.6K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Positive Regulator Molecules
5.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K
